27/06/2024 - Press release
Gastric bypass is more effective than the other common approach, vertical sleeve gastrectomy, in reducing LDL cholesterol levels. This is a common comorbidity in patients undergoing this type of surgery and a primary agent causing atherosclerosis. This is revealed in a study by the Bariatric Surgery Unit at Hospital del Mar, published in the journal Cardiovascular Diabetology. The study's authors argue that this fact should be considered when deciding which technique to use for each patient.
19/06/2024 - Institutional news
Anna Bigas, coordinator of the Stem Cells and Cancer Group at the Hospital del Mar Research Institute, scientific director of CIBERONC, and deputy director of preclinical research at the Josep Carreras Institute, is part of the organizing committee. The event featured more than ten national and international speakers and 135 participants.
18/06/2024 - Institutional news
These are two international clinical trials, LAURA and ADRIATIC, which confirm the positive effect of consolidation with systemic therapies following the combination of chemotherapy in two patient populations.
13/06/2024 - General information
The director of the center's Epilepsy Unit and coordinator of the Epilepsy Research Group at its research institute has received this distinction at the society's institutional event, held in Santiago de Compostela. Dr. Rodrigo Rocamora has received the 2023 Epilepsy Award in its scientific category from the Spanish Society of Neurology. The award ceremony took place during the society's institutional event, held on June 6 in Santiago de Compostela.
Més informació "2023 Epilepsy Award from the Spanish Society of Neurology for Dr. Rodrigo Rocamora."
05/06/2024 - Press release
A scientific team led by Dr Anna Bigas, from the Hospital del Mar Research Institute and the Josep Carreras Institute, has described the role of the IκBα protein in the differentiation process of haematopoietic cells. In the absence of this protein, the stem cells enter quiescence, acquire a dormant state and maintain their potential, which may allow them to be transplanted for therapeutic uses in leukaemia or blood diseases of genetic origin. This is an important step towards being able to generate these types of cells in the lab, preventing them from differentiating and turning into other cells too early.
29/05/2024 - Press release
An international study led by the Hospital del Mar Medical Research Institute has demonstrated, for the first time, the role of two proteins in the activation and deactivation of the system through which drugs act against schizophrenia symptoms. These two proteins are potential targets for developing new drugs aimed at specific symptoms of the disease, avoiding the side effects of current treatments. The study analyzed how certain molecules act on a serotonin cell receptor, which could allow for differentiated effects on schizophrenia symptoms without affecting other brain processes.
Més informació "New Avenues to Developing Personalized Treatments for Schizophrenia"
22/05/2024 - Institutional news
From March 8 to June 28, hundreds of people will witness firsthand the advancements in scientific knowledge about various diseases, thanks to the drive of solidarity, in a new cycle of visits to research centers with projects funded by the La Marató de TV3 Foundation. At the Hospital del Mar Research Institute, we are participating in this initiative by organizing four visits where different projects funded by the 2021 Mental Health Marathon will be explained. On May 27 and 28, we will discuss the project led by Dr. Gabriel Santpere, who, together with Dr. Patricia Robledo, proposes a highly innovative methodology to predict the risk of developing schizophrenia. This will be done by combining information from nasal cavity neurons (olfactory neuroepithelium), genetics, and brain imaging from a group of people with and without symptoms of the disease. Registrations for the visits are free and can be made on this page:
Més informació "Once again we participate in "Visit the research of La Marató"."
21/05/2024 - Press release
A systematic review and meta-analysis of the scientific evidence published between 2000 and 2021 estimates the recurrence risk in people who have suffered a minor stroke, a stroke that does not cause sequelae. The study is published by the Journal of the American Heart Association and includes participation from the Neurology Service of Hospital del Mar. Almost one in ten people who suffer a stroke without sequelae, known as a minor stroke, will experience a second stroke within three months of the first episode. This is established by a recent study led by researchers from the University of Melbourne in Australia, with participation from the Neurology Service of Hospital del Mar. The work, a systematic review and meta-analysis of 14 publications on the subject, is published by the Journal of the American Heart Association. It is the largest study on this type of pathology conducted to date.
16/05/2024 - General information
13th May 2024 - Hospital del Mar Research Institute, Barcelona, Spain 15th May 2024 - Grande Ospedale Metropolitano Niguarda, Milan, Italy Physicians, scientists, health economics researchers, data and communication experts from the Horizon Europe project SAGITTARIUS joined oncology specialists and members of an EU-wide community of cancer centres in Barcelona and Milan to present the SAGITTARIUS clinical study, a new EU-funded clinical trial leveraging the power of tumor genomics and liquid biopsy to guide the post-surgical care of patients with locoregional colon cancer
15/05/2024 - Institutional news
The admission was approved at the meeting of the organization held on April 9th in Mannheim, Germany. The Research Institute of the Hospital del Mar is one of the five new members of the European Leukemia Net, an international network of excellence to promote cooperative research in different types of leukemias. Its admission was approved at the meeting of the organization held on April 9th in Mannheim, Germany. Dr. Blanca Espinet, coordinator of the Translational Research Group in Hematological Neoplasms and head of the Molecular Cytogenetics section of the Pathological Anatomy Service of Hospital del Mar, is the principal investigator representative of the center.
Més informació "The Research Institute of Hospital del Mar joins the European LeukemiaNet."
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact